Amwill Health Care Ltd Company Summary

Amwill Health Care Ltd Summary

Amwill Health Care Limited was originally incorporated on August 21, 2017 under the name Amwill Health Care Private Limited, dated August 22, 2017 issued by the Deputy Registrar of Companies, Karnataka at Bangalore. Further, Company was converted into a Public Limited Company and a fresh Certificate of Incorporation dated January 25, 2024 was issued by the Registrar of Companies, Karnataka at Bangalore with the change in name to Amwill Health Care Limited.Amwill Health Care Ltd is a derma-cosmetic development company, associated with contract manufacturers, distributor and third party product development agencies, which has enabled in developing capabilities, in manufacturing, packaging and distribution. The core focus of Company is on development of problem solving dermatological, cosmeceutical and aesthetical products, and therefore to direct all efforts towards product formulation and development, the Company has outsourced key functions such as manufacturing, prototype development and distribution to third parties, for effective management and execution. The product profile of Company is divided into two categories, development and contract manufacturing of generic dermatological solutions; and developing and formulating solutions to specific dermatological problem. Majority of products marketed by them, were developed by Promoter, Anand Gandhi, in the capacity of a sole proprietor of M/s. Amwill Healthcare.The Company registered the first transaction of sale of cosmetic products in the year 2020. It launched a new product under the name XL-HYDRA, a face moisturiser and launched a new formulation in hair-care therapy under the name- Fin-XL Pro Gel in a gel based formulation in 2021. The Company has created a structured storage and distribution chain through one of its promoter group entities, M/s. Amderma Healthcare LLP, which was established under the guidance of Tarun Gandhi. It has entered into a carrying and forwarding agreement dated May 15, 2024 effective from January 1, 2024, with Amderma, for appointing Amderma as a Carrying and Forwarding Agent. The Company is planning the Initial Public Offer aggregating 62,00,000 Equity Shares consisting a Fresh Issue of 50,00,000 Equity Shares and an Offer for Sale of 12,00,000 Equity Shares.